tetano
Editor, Senior Moderator
Trends Immunol
. 2020 Sep 23;S1471-4906(20)30229-5.
doi: 10.1016/j.it.2020.09.008. Online ahead of print.
The Complement C5a-C5aR1 GPCR Axis in COVID-19 Therapeutics
Trent M Woodruff[SUP] 1 [/SUP], Arun K Shukla[SUP] 2 [/SUP]
Affiliations
Abstract
The current pandemic of coronavirus disease (COVID-19) caused by SARS-CoV-2 is a significant global health challenge. A recent study by Carvelli and colleagues now demonstrates the involvement of complement C5a and its receptor C5aR1 in disease progression and suggests that blockade of the C5a-C5aR1 axis may represent a potential therapeutic strategy against COVID-19.
Keywords: COVID-19; GPCRs; SARS-CoV-2; cellular signaling; complement system; drug discovery.
. 2020 Sep 23;S1471-4906(20)30229-5.
doi: 10.1016/j.it.2020.09.008. Online ahead of print.
The Complement C5a-C5aR1 GPCR Axis in COVID-19 Therapeutics
Trent M Woodruff[SUP] 1 [/SUP], Arun K Shukla[SUP] 2 [/SUP]
Affiliations
- PMID: 33023856
- DOI: 10.1016/j.it.2020.09.008
Abstract
The current pandemic of coronavirus disease (COVID-19) caused by SARS-CoV-2 is a significant global health challenge. A recent study by Carvelli and colleagues now demonstrates the involvement of complement C5a and its receptor C5aR1 in disease progression and suggests that blockade of the C5a-C5aR1 axis may represent a potential therapeutic strategy against COVID-19.
Keywords: COVID-19; GPCRs; SARS-CoV-2; cellular signaling; complement system; drug discovery.